Skip to content

Licorice Influences on cortisol/cortisone, electrolytes and blood pressure

Licorice Influences on cortisol/cortisone, electrolytes and blood pressure - LICORICE study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON46407
Enrollment
40
Registered
2018-01-29
Start date
2018-02-09
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bloeddruk, elektrolyten, cortison/cortisol balans High bloodpressure hypertension

Interventions

None listed

Sponsors

Academisch Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Willing and able to participate in the study protocol - Written informed consent - Age 18-60 years - Office diastolic blood pressure maximal 90 mmHg and office systolic blood pressure maximal 140 mmHg - BMI > 18 or

Exclusion criteria

Exclusion criteria: - Allergy to one of the ingredients of licorice - Office blood pressure >140/90 mm - Reported alcohol consumption > 28 units/week or recreational drug use - Existing cardiovascular diseases - Use of medication which affects the primary or secondary outcome measurements such as diuretics, antihypertensive drugs and NSAIDs 200 gr/week) or >3 litre of licorice tea per week - Pregnancy

Design outcomes

Primary

MeasureTime frame
The primary outcome will be the difference in 24-hour ambulatory systolic and diastolic blood pressure after exposure to a fixed dose of licorice

Secondary

MeasureTime frame
Secondary outcome parameters will be the difference in cortisol/cortisone ratio, potassium, sodium and aldosterone excretion in 24h urine collection. Furthermore, the difference in concentrations of plasma potassium, sodium, eGFR, creatinine, aldosterone and plasma renin activity will be measured. In addition, we will determine the individual weight at the end of the run-in period (screening) and at the end of the intervention period. Finally, an exploratory analysis for single nucleotide polymorphisms in the gene encoding for 11-beta-hydroxysteroiddehydrogenase will be performed in those five participants with the greatest increase in blood pressure

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)